Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement

Completed · Phase 2

Conditions studied: Arthroplasty, Replacement, Hip, Thrombosis

In brief

Patients who undergo total hip replacement surgery are at greater risk of getting deep vein thrombosis (blood clots). This study evaluates the safety, tolerability and effectiveness of the study drug, DU-176b, in reducing the occurrence of deep vein thrombosis in patients having total hip replacement surgery.

Key facts

Study ID

NCT00107900

Run by

Daiichi Sankyo

People needed

606

Starts

2005-01-01

Expected to finish

2005-12-01

Last updated by the study team

2019-02-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Unilateral hip replacement

You may not qualify if…

• Patients scheduled for bilateral hip replacement in same procedure
• Patients with increased risk of bleeding
• Uncontrolled hypertension (BP greater than 180/100 mmHg)
• Patients less than 111 lbs or more than 243 lbs
• Patients on long-term anticoagulants
• Patients with contraindications to venography
• Patients with medical history of venous thromboembolism
• Patients with impaired hepatic function
• Known to be pregnant
• Lactating women

Where it is running

• Local Institution — Decatur, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.